Kintara Therapeutics (STU:3DMA) Operating Cash Flow per Share : €-2.04 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Operating Cash Flow per Share?

Kintara Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was €-0.05. Kintara Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 42.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 47.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Kintara Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

STU:3DMA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -565.2 Med: 11.15 Max: 51.6
Current: 42.2

During the past 13 years, Kintara Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.60% per year. The lowest was -565.20% per year. And the median was 11.15% per year.

STU:3DMA's 3-Year OCF Growth Rate is ranked better than
87.47% of 1237 companies
in the Biotechnology industry
Industry Median: 3.3 vs STU:3DMA: 42.20

Kintara Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Kintara Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Operating Cash Flow per Share Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-109.78

-33.68

-30.22

-19.81

-6.76

Kintara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.02	-0.82	-0.72	-0.45	-0.05

Competitive Comparison of Kintara Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Kintara Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Price-to-Operating-Cash-Flow falls into.

Kintara Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Kintara Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )	=	Cash Flow from Operations (A: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2023 )
	=	-10.951	/	1.620
	=	-6.76

Kintara Therapeutics's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-2.116	/	44.562
	=	-0.05

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.04

Kintara Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines